Alvotech (NASDAQ:ALVO) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Alvotech (NASDAQ:ALVO – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $4.20 and traded as low as $4.13. Alvotech shares last traded at $4.19, with a volume of 2,091,332 shares changing hands.

Key Stories Impacting Alvotech

These are some of the ALVO stories that stood out recently:

  • Positive Sentiment: Alvotech forecast 2026 revenue of $650 million–$700 million, broadly around or above the $652.5 million consensus at the midpoint, and EBITDA of $180 million–$220 million. Management said it expects the fourth quarter to be the strongest in company history. Article: Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA
  • Neutral Sentiment: The earnings call highlighted growth opportunities alongside business risks; the available article summary did not specify further details. Article: Alvotech Earnings Call Highlights Growth and Risks
  • Negative Sentiment: Q3 revenue of $111.6 million fell short of the $125.2 million analyst estimate. Alvotech posted a loss of $0.03 per share; while that beat one reported consensus estimate of a $0.04 loss, it missed Zacks’ estimate of a $0.01 loss. The revenue miss and mixed earnings comparisons could pressure the shares. Article: Alvotech Reports Q3 Loss, Lags Revenue Estimates

Analysts Set New Price Targets

ALVO has been the subject of a number of research analyst reports. Jefferies Financial Group assumed coverage on Alvotech in a report on Tuesday, November 10th. They issued a “buy” rating and a $9.00 price target for the company. Barclays raised shares of Alvotech from an “underweight” rating to an “overweight” rating and increased their price objective for the stock from $4.00 to $8.00 in a report on Wednesday, September 16th. Bank of America initiated coverage on shares of Alvotech in a research report on Monday, August 24th. They issued a “buy” rating and a $7.00 price objective for the company. Evercore began coverage on shares of Alvotech in a research note on Friday, August 14th. They issued an “outperform” rating for the company. Finally, UBS Group set a $8.00 target price on shares of Alvotech in a research report on Wednesday, September 16th. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.40.

Get Our Latest Stock Analysis on Alvotech

Alvotech Stock Performance

The stock has a 50-day simple moving average of $5.23 and a 200 day simple moving average of $4.20. The stock has a market capitalization of $1.26 billion, a P/E ratio of -5.11 and a beta of 0.24.

Alvotech (NASDAQ:ALVO – Get Free Report) last released its earnings results on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $111.60 million for the quarter, compared to the consensus estimate of $123.45 million. Equities analysts predict that Alvotech will post -0.01 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new stake in shares of Alvotech during the second quarter worth approximately $6,376,000. Renaissance Technologies LLC lifted its holdings in Alvotech by 146.9% in the first quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock valued at $217,000 after buying an additional 37,600 shares during the period. Marshall Wace LLP bought a new position in Alvotech in the third quarter valued at approximately $2,326,000. State Street Corp bought a new position in Alvotech in the third quarter valued at approximately $594,000. Finally, Royce & Associates LP acquired a new stake in Alvotech during the 3rd quarter worth $3,817,000.

Alvotech Company Profile

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

Read More

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.